Graft-Versus-Host Disease
Completed Trials
Graft-Versus-Host Disease
Researchers studied biomarkers of patients prior to Hematopoietic Cell Transplantation (HCT). Compared to 16 healthy control patients, "pre-transplant patients came to transplant with abnormal levels of all three biomarkers, reflecting residual damage from prior chemotherapy." The study suggests that pre-HCT interventions to the gut microbiome may decrease patient risk for Graft-Versus-Host disease post HCT. Read the study publication here.
Hear more about Graft versus Host disease from Dr. Shernan Holtan, researcher at the University of Minnesota.
Achieving Cures Together is tax exempt pursuant to IRC Section 501(c)(3). Contributions are deductible to the extent allowed by law.
